DCTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Delcath Systems Inc (DCTH) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows potential growth in revenue and has a positive long-term outlook with label expansion and HEPZATO commercialization, the current financial performance, technical indicators, and lack of strong trading signals suggest that this is not an optimal entry point. The stock's recent price decline and lack of immediate positive catalysts make it prudent to hold off on buying for now.
The MACD is slightly positive but contracting, indicating weakening momentum. RSI is neutral at 51.441, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 10.597, with key resistance at 11.113 and support at 10.082. Overall, the technical indicators do not signal a strong buy opportunity.
Analyst maintains a Buy rating with a price target of $27, citing potential growth from HEPZATO commercialization and label expansion. Revenue growth of 37.27% YoY in Q4 2025 indicates strong sales momentum.
Recent price action shows a 4.92% decline in the regular market session.
In Q4 2025, revenue increased by 37.27% YoY to $20.73M, showing strong top-line growth. However, net income dropped to -$1.896M, down 44.20% YoY, and EPS fell to -0.05, down 54.55% YoY. Gross margin slightly declined to 85.48%. The company is investing heavily in R&D and SG&A for future growth, which is impacting short-term profitability.
Clear Street lowered the price target from $29 to $27 but maintained a Buy rating. The firm believes the stock's weakness is due to short-term concerns over 2026 guidance, but it remains optimistic about long-term growth drivers like HEPZATO commercialization and label expansion.
